Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report
Kevin C Cronin1, Gabrielle C Colleran, Andrew Smyth
1Department of Surgery, Galway University Hospital, Newcastle Road, Galway, Ireland. chieftaincronin@gmail.com
Abstract:
A 32-year-old male presented with diarrhoea, mucus and bleeding per rectum. On the basis of sigmoidoscopy, rectal mesalazine was commenced uneventfully, and subsequently changed to oral mesalazine due to failure to improve.He re-presented 4 days later with frequent rigors, lethargy, palpitations and was generally unwell. His condition settled with conservative management and IV antibiotics.Oral mesalazine was withheld during the first 24 hours but was recommenced on day 2. After 2 doses he developed rigors, pyrexia, tachycardia and vomiting.Oral mesalazine was discontinued thereafter and his condition progressively improved. Mesalazine has not been re-introduced.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease IV: Clinical Manifestations

